针对关节相关肽的自身抗体作为早期类风湿关节炎的预测标志物
研究在瑞典BARFOT和TIRA-2两个新发类风湿关节炎队列(n=1986)中,用珠基多重流式免疫分析法筛查针对关节相关肽(JointIDs)的自身抗体,并以Boolean缓解1.0、肿胀关节数和影像学破坏为结局,用多因素逻辑回归及零膨胀负二项模型分析。结果显示,针对未修饰II型胶原肽的抗体阳性男性患者在12个月时预测Boolean缓解的敏感性为42%、特异性为75%;抗CCP抗体预测关节破坏特异性低(58%)。
要点
- 抗未修饰COL2肽抗体阳性男性患者12个月Boolean缓解预测敏感性42%、特异性75%。
- 抗瓜氨酸化COMP肽抗体阴性且6个月达Boolean缓解者,敏感性13%、特异性99%。
- 抗未修饰COL2肽抗体阳性使6个月和12个月肿胀关节频率分别降低41%和33%。
核心结论
- RA诊断时针对关节相关蛋白的自身抗体以高特异性预测缓解,结合临床因素可能指导未来治疗决策。
研究设计与样本
- 研究纳入瑞典BARFOT和TIRA-2两个新发RA队列患者共n=1986例,检测血清中针对选定肽(JointIDs)的自身抗体。
- 采用珠基多重流式免疫分析法筛查自身抗体,结局包括Boolean缓解1.0、肿胀关节数和影像学破坏。
- 使用多因素逻辑回归和零膨胀负二项模型(校正临床因素)筛选预测预后潜力最强的JointIDs。
主要发现
- 抗未修饰II型胶原(COL2)肽抗体阳性男性患者12个月Boolean缓解预测敏感性42%、特异性75%。
- 抗特定瓜氨酸化软骨寡聚蛋白(COMP)肽抗体阴性且6个月达Boolean缓解时,敏感性13%、特异性99%。
- 抗未修饰COL2肽抗体阳性使6个月和12个月肿胀关节频率分别降低41%和33%。
- 抗CCP抗体预测关节破坏特异性低(58%)。
- 瓜氨酸化形式的COL2肽和葡萄糖-6-磷酸脱氢酶肽抗体阳性使特异性提高至86%,但敏感性降至39%。
临床怎么用
- 作者认为,RA诊断时针对关节相关蛋白的自身抗体以高特异性预测缓解,结合临床因素可能指导未来治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For better management of RA, new biomarkers are needed to predict the development of different disease courses. This study aims to identify autoantibodies against epitopes on proteins in the joints and to predict disease outcome in patients with new onset RA. METHODS: Sera from new-onset RA patients from the Swedish BARFOT (Better Anti Rheumatic PharmacOTherapy) and TIRA-2 (Swedish acronym for 'tidiga insatser vid reumatoid artrit') cohorts (n = 1986) were screened for autoantibodies to selected peptides (JointIDs) in a bead-based multiplex flow immunoassay. Disease outcomes included Boolean remission 1.0, swollen joint count and radiographic destruction. Multivariate logistic regression and zero-inflated negative binomial models that accounted for clinical factors were used to identify JointIDs with the strongest potential to predict prognosis. RESULTS: Boolean remission was predicted with 42% sensitivity and 75% specificity in male patients positive for antibodies to a non-modified collagen type II (COL2) peptide at 12 months. When antibodies to a specific citrullinated cartilage oligomeric protein (COMP) peptide were absent and the patient was in Boolean remission at 6 months, the sensitivity was 13% and the specificity 99%. Positivity for the non-modified COL2 peptide also reduced the frequency of swollen joints by 41% and 33% at 6 and 12 months, respectively. Antibodies to CCP predicted joint destruction with low specificity (58%). Positivity for a COL2 and a glucose-6-phosphate dehydrogenase peptide in citrullinated forms increased specificity (86%) at the expense of sensitivity (39%). CONCLUSION: Autoantibodies against joint-related proteins at RA diagnosis predict remission with high specificity and, in combination with clinical factors, may guide future treatment decisions.
引用
- Leu Agelii M, Sareila O, Lönnblom E, et al. Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 39078716. doi:10.1093/rheumatology/keae382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。